A Study of 131I-Tositumomab (Bexxar®) Consolidation in Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 16
- Locations
- 1
- Primary Endpoint
- Probability of Progression-free Survival (PFS)
Study Overview
Brief Summary
This phase II trial studies how well tositumomab and iodine I 131 tositumomab works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have had their first decrease in or disappearance of signs and symptoms of cancer (first remission). Monoclonal antibodies, such as tositumomab and iodine I 131 tositumomab, may block cancer growth in different ways by targeting certain cells.
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate the progression-free survival at 2 years following administration of 131I-tositumomab (tositumomab and iodine I 131 tositumomab) in patients with CLL/SLL who achieve a complete remission (CR) or partial remission (PR) with prior therapy.
II. To improve the response rate by administering 131I-tositumomab to patients who have achieved a PR not a CR after any prior therapy.
III. To eliminate residual disease (documented by flow cytometry or polymerase chain reaction [PCR]) using 131I-tositumomab in patients who have achieved a CR after any prior therapy.
SECONDARY OBJECTIVES:
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients with a diagnosis of cluster of differentiation (CD)20+ CLL/SLL; prior to the first treatment patients with CLL must have been either Rai stage III/IV disease or Rai stage I/II with evidence of disease activity as defined by the National Cancer Institute (NCI) 1996 guidelines, and patients with SLL must have been Stage III or IV per Ann Arbor staging system
- •Patient has received prior therapy and is in 1st remission with a partial or complete response to treatment
- •Patients must have no more than 25% of the intratrabecular marrow space involved by leukemia in bone marrow biopsy specimens as assessed microscopically after completion of treatment; bilateral posterior iliac crest core biopsies are required if the percentage of intratrabecular space involved exceeds 10% on a unilateral biopsy; the mean of bilateral biopsies must be no more than 25%
- •Patient must have consented to participate in the study and signed and dated an appropriate institutional review board (IRB)-approved consent form that conforms to federal and institutional guidelines
- •Patient must have a Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (0 = fully active, able to carry on all pre-disease performance without restriction; 1 = restricted in physically strenuous activity but ambulatory and ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care but unable to carry out any work activities and is up and about more than 50% of waking hours)
- •Patient must have an anticipated survival of at least 3 months
- •Granulocytes >= 1,500/uL within 14 days of planned dosimetric infusion
- •Platelets >= 100,000/uL within 14 days of planned dosimetric infusion
- •White blood count =< 20,000/mm^3
- •Serum creatinine < 2 times upper limit of normal
- •Total bilirubin < 2 times upper limit of normal
- •Aspartate aminotransferase (AST) < 5 times upper limit of normal
- •Males and females must agree to use a contraceptive method from enrollment to 6 months after receiving I-131 labeled tositumomab
Exclusion Criteria
- •Patients who have received prior radiolabeled antibody
- •Patients with active hemolysis
- •Patients must not require sustained transfusion support of blood products
- •Patients in 2nd remission or beyond
- •Patients who have undergone treatment with either stem cell or bone marrow transplant
- •Patients with active obstructive hydronephrosis
- •Patients with evidence of any significant systemic illness, active hepatitis B infection or other active infection at the time of study entry
- •Patients with New York Heart Association class III or IV heart disease or other serious illness that would preclude evaluation
- •Patients with known human immunodeficiency virus (HIV) infection
- •Patients who are pregnant or nursing
- •Patients with prior malignancy other than CLL/SLL, except for adequately treated skin cancer (basal cell or squamous cell carcinoma), in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years unless approved by the principal investigator (PI)
- •Patients with active brain or leptomeningeal involvement by malignancy
- •Patients who have, in the opinion of the investigator, other medical, social, or psychosocial factors that may negatively impact compliance or their safety by participation in this study
Arms & Interventions
Treatment (monoclonal antibody therapy)
Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
Intervention: Tositumomab and Iodine I 131 Tositumomab (Combination Product)
Outcomes
Primary Outcomes
Probability of Progression-free Survival (PFS)
Time Frame: 36 months
Progression free survival (PFS) is defined as the interval between the first treatment day to the first sign of disease progression. This outcome measures the percentage of participants with PFS at 36 months.
Improved Response Rate After Treatment With 131I-tositumomab for Patients Who Had Evidence of CLL at the End of Initial Chemotherapy
Time Frame: 3 months after 131I-tositumomab consolidation
Response rates determined using National Cancer Institute (NCI) working group guidelines plus computed tomography (CT) scan criteria. Participants were assessed for response after initial chemotherapy and again 3 months after 131I-tositumomab treatment.Only patients who had less than a complete response (CR) after initial chemotherapy were assessed for improved response after 131I-tositumomab.
Minimal Residual Disease (MRD) by Flow Cytometry or Polymerase Chain Reaction (PCR) in Patients Who Had a Complete Remission (CR) After Any Prior Therapy
Time Frame: 3 months after 131I-tositumomab consolidation
Secondary Outcomes
- Evaluate Toxicities of 131I-tositumomab(48 months (median))
Investigators
Mazyar Shadman
Principal Investigator
Fred Hutchinson Cancer Center